L189 inhibits base excision repair (BER) and non-homologous end joining (NHEJ), which specifically sensitizes cancer cells to DNA damage and increases the cytotoxicity of DNA-damaging agents. L189 will not only provide insights into the cellular function of these enzymes but also serve as lead compounds for the development of anticancer agents.
For research use only. We do not sell to patients.